NLRC3 and cancer: Conversely, several tumor suppressors (e.g. NLRC3 (88)) associated with immune-relevant pathways (e.g. chemokine signaling and T-cell receptor signaling) were found to be the most frequently correlated with favorable outcomes in certain cancers, reflecting the roles of the immune system in antagonizing tumor development and progression (68,113).